相关实验视频

Updated: May 6, 2026

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle

Published on: February 1, 2017

定量HBeAg是接受基化干扰素的患者中HBeAg损失的强有力的预测因素

Daniel Q Huang¹, Liang Shen², Wah Wah Phyo³

¹Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore; Division of Gastroenterology and Hepatology, National University Health System, Singapore.

Antiviral research

|April 19, 2024

概括

量化B型肝炎抗原 (HBeAg) 损失是慢性乙型肝炎 (CHB) 治疗的关键. 这项研究发现,基线和治疗期间的定量HBeAg水平可以预测哪些CHB患者在核胺类模拟疗法上可能受益于添加基化干扰素.

科学领域:

肝病学肝病学是一种肝病学.
病毒学病毒学
免疫学免疫学免疫学

背景情况:

HBeAg损失是慢性乙型肝炎 (CHB) 抗病毒疗法的关键终点.
目前,缺乏可靠的生物标志物来预测治疗对核化干扰素 (PegIFN) 添加的治疗反应,这些患者接受了核化类似物 (NA).

研究的目的:

研究血清生物标志物的预测价值,以实现NA治疗中CHB患者的HBeAg损失.
在添加或切换到PegIFN治疗时识别HBeAg损失的预测因子.

主要方法:

这项研究评估了接受NAs的HBeAg阳性CHB参与者,这些参与者在48周的PegIFN alpha2b治疗中被切换到或添加到NAs.
包括定量HBeAg (qHBeAg),定量HBsAg (qHBsAg) 和HBVRNA在内的血清生物标志物在基线和治疗期间被评估.
分析了这些生物标志物的预测能力和72周HBeAg损失的临床变量.

主要成果:

在完成48周PegIFN治疗的27.3%的参与者中观察到HBeAg损失.
较低的基线qHBeAg水平与HBeAg损失显著相关 (P=0.007).
HBeAg损失的独立预测因素包括较低的基线qHBeAg (OR=0.15) 和可检测的基线HBVDNA (OR=25.00). 在治疗中的qHBeAg也强烈预测了HBeAg损失 (OR=0.39).
结合基线HBVDNA与基线或治疗中的qHBeAg的模型在预测HBeAg损失方面表现出很好的准确性 (C统计数据0.82-0.83).

结论:

在基线和治疗期间的定量HBeAg (qHBeAg) 作为一种有价值的生物标志物.
qHBeAg可以识别接受NA治疗的CHB患者,他们可能会从添加或切换到PegIFN中受益.
这些发现有助于个性化慢性乙型肝炎的抗病毒治疗策略.

关键词:

生物标志物生物标志物在HBeAg中使用.乙型肝炎 B 型肝炎化干扰素干扰素的使用方法

更多相关视频

Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix

Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix

Published on: October 20, 2021

Author Spotlight: Advancements and Challenges in Hepatitis B Virus Detection

Author Spotlight: Advancements and Challenges in Hepatitis B Virus Detection

Published on: December 15, 2023

相关概念视频

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...

Hepatitis

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver.